More on BAYZF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $43.87 |
|
|||
| Open | $42.53 | ||||
| 52 Wk High | $135.00 | ||||
| 52 Wk Low | $94.95 | ||||
| Day High | $42.53 | ||||
| Day Low | $42.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 686 | ||||
- FDA clears Bayer's MEDRAD MRXperion system for 7T MRI compatibility
- New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
- Bayer reports phase I results for prostate cancer therapy
- Bayer Reports Results for the Investigational Targeted Radionuclide Therapy ²²⁵Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
- Bayer's XOFIGO plus enzalutamide reduces death risk by 24% in prostate cancer
- Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bo
- Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
- Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
- Bayer's asundexian reduces stroke risk by 26% in phase III trial
- Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus
Entities mentioned with BAYZF
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Tesla | View Related Stories »
- JPMorgan | View Related Stories »
- Twitter | View Related Stories »
- Show More...
